Expression of p53, p27 and Jab1 protein in epithelial ovarian tumors

Objective: The study aimed to investigate expression of p53, p27 and Jun activation domain-binding protein 1 (Jab1) proteins in epithelial ovarian tumors and the values of these factors as discriminating markers for the transformation of borderline tumors to cancers. Methods: Forty-seven cases of paraffin-embedded tissues of epithelial ovarian tumors including 22 cases of benign ovarian tumors, nine cases of borderline tumors, and 16 cases of invasive cancers were used to evaluate expression of p53, p27 and Jab1 proteins by immunohistochemical methods. Results: p53 protein was expressed in 13.6% of the benign tumors, 44.4% of the borderline tumors and 62.5% of the malignant tumors and p27 protein was expressed in 95.5% of the benign tumors, 66.7% of the borderline tumors, and 37.5% of the malignant tumors. Expression of Jab1 protein was observed in 22.7% of the benign tumors, 77.8% of the borderline tumors and 62.5% of the malignant tumors. Expressions of p53, p27 and Jab1 proteins in malignant tumors were all higher than in benign tumors and the expression of p27 protein in malignant tumors was lower than in benign tumors (p < 0.05). Expression of Jab1 protein in borderline tumors was significantly higher than in benign tumors (p < 0.05). Conclusions: Expression of p53, p27 and Jab1 proteins can be used to discriminate between benign and malignant tumors in epithelial ovarian tumors.

p53; p27; Jab1; Borderline tumor

[1] Taylor H.C.: “Malignant and semimalignant tumors of the ovary”. Surg. Gynecol. Obstet., 1929, 48, 204.

[2] International Federation of Gynecology and Obstetrics: “Classification and staging of malignant tumours in the female pelvis”. Acta Obstet Gynecol Scand, 1971, 50, 1.

[3] Ozols R.F., Rubin S.C., Thomas G.M., Robboy S.J.: “Epithelial ovarian cancer”. In: Hoskins W.J., Young R.C., Perez C.A., Barakat R., Randall M. (eds.). Principles and Practice of Gynecologic Oncology, 4th edition, Philadelphia, Lippincott Williams and Wilkins, 2005, 895.

[4] Seidman J.D., Ronnett B.M., Kurman R.J.: “Pathology of borderline (low malignant potential) ovarian tumours”. Best Pract. Res. Clin. Obstet. Gynaecol., 2002, 16, 499.

[5] Sherr C.J.: “Cancer cell cycles”. Science, 1996, 274, 1672.

[6] Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A.: “High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene”. Mol. Cell. Biol., 1989, 9, 3982.

[7] Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M. et al.: “p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest”. Genes Dev., 1994, 8, 9.

[8] Tomoda K., Kubota Y., Kato J.: “Degradation of the cyclindependent- kinase inhibitor p27Kip1 is instigated by Jab1”. Nature, 1999, 398, 160.

[9] Harris A.L.: “Mutant p53—the commonest genetic abnormality in human cancer?”. J. Pathol., 1990, 162, 5.

[10] Rajesh N.G., Rekha K., Krishna B.: “Significance of p53 expression in ovarian tumors and its correlation to the morphological differentiation”. Indian J. Pathol. Microbiol., 2007, 50, 284.

[11] Berchuck A., Kohler M.F., Hopkins M.P., Humphrey P.A., Robboy S.J., Rodriguez G.C. et al.: “Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors”. Gynecol. Oncol., 1994, 52, 232.

[12] Marcelli A.R., Demopoulos R.I., Goswami S., Mittal K.R.: “Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors”. Int. J. Gynecol. Pathol., 1996, 15, 39.

[13] Kupryjanczyk J., Bell D.A., Yandell D.W., Scully R.E., Thor A.D.: “p53 expression in ovarian borderline tumors and stage I carcinomas”. Am. J. Clin. Pathol., 1994, 102, 671.

[14] Bullrich F., MacLachlan T.K., Sang N., Druck T., Veronese M.L., Allen S.L. et al.: “Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer”. Cancer Res., 1995, 55, 1199.

[15] Patah L.E., Camarotto K.C., Goncalves W.J.: “P27 expression in epithelial ovarian tumors”. Int. J. Gynaecol. Obstet., 2004, 85, 179.

[16] Goff B.A., Paley P.J., Greer B.E., Gown A.M.: “Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma”. Gynecol. Oncol., 2001, 81, 18.

[17] Slingerland J., Pagano M.: “Regulation of the cdk inhibitor p27 and its deregulation in cancer”. J. Cell. Physiol., 2000, 183, 10.

[18] Newcomb E.W., Sosnow M., Demopoulos R.I., Zeleniuch- Jacquotte A., Sorich J., Speyer J.L.: “Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors”. Am. J. Pathol., 1999, 154, 119.

[19] Masciullo V., Sgambato A., Pacilio C., Pucci B., Ferrandina G., Palazzo J. et al.: “Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer”. Cancer Res., 1999, 59, 3790.

[20] Baekelandt M., Holm R., Trope C.G., Nesland J.M., Kristensen G.B.: “Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study”. Clin. Cancer Res., 1999, 5, 2848.

[21] Catzavelos C., Bhattacharya N., Ung Y.C., Wilson J.A., Roncari L., Sandhu C. et al.: “Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer”. Nat. Med., 1997, 3, 227.

[22] Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J. et al.: “Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients”. Nat. Med., 1997, 3, 222.

[23] Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C. et al.: “The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas”. Cancer Res., 1997, 57, 1259.

[24] Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F. et al.: “Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas”. Nat. Med., 1997, 3, 231.

[25] Claret F.X., Hibi M., Dhut S., Toda T., Karin M.: “A new group of conserved coactivators that increase the specificity of AP-1 transcription factors”. Nature, 1996, 383, 453.

[26] Sui L., Dong Y., Ohno M., Watanabe Y., Sugimoto K., Tai Y. et al.: “Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors”. Clin. Cancer Res., 2001, 7, 4130.

[27] Marks J.R., Davidoff A.M., Kerns B.J., Humphrey P.A., Pence J.C., Dodge R.K. et al.: “Overexpression and mutation of p53 in epithelial ovarian cancer”. Cancer Res., 1991, 51, 2979.

[28] Kohler M.F., Kerns B.J., Humphrey P.A., Marks J.R., Bast R.C., Jr., Berchuck A.: “Mutation and overexpression of p53 in earlystage epithelial ovarian cancer”. Obstet. Gynecol., 1993, 81, 643.